Slide 1: Stevanato Group Q1 2025 Financial Results
Stevanato Group Q1 2025 Financial Results May 8, 2025
Slide 2: Safe Harbor Statement
Safe Harbor Statement Forward-Looking Statements This presentation contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that reflect the current views of Stevanato Group S.p.A. (“we”, “our”, “us”, “Stevanato Group” or the “Company”) a
Slide 3: Stevanato Group Q1 2025 Financial Results Earnings Call
Stevanato Group Q1 2025 Financial Results Earnings Call Franco Marco Lisa Stevanato Dal Lago Miles Chairman & CEO CFO CCO and IR Q1 2025 Financial Results 3
Slide 4: Franco Stevanato
x Franco Stevanato Chairman & Chief Executive Officer Q1 2025 Financial Results
Slide 5: Started 2025 with Strong Momentum Highlighted by 9% Revenue Growth and a Step-Up in Margins
Started 2025 with Strong Momentum Highlighted by 9% Revenue Growth and a Step-Up in Margins Strong operational delivery in the BDS Segment Soft performance in Engineering, as expected • Expected improvements at our Latina and Fishers facilities • Revenue and margin decline primarily related to legac
Slide 6: Demand-Driven Capacity Expansion Update
Demand-Driven Capacity Expansion Update Continued financial improvement in margins, as we begin to scale volumes, utilization, and revenue Fishers (IN), U.S. Latina, Italy Supporting U.S. customers across the full value chain, Diversifying EMEA footprint with expanding capacity strategically focused
Slide 7: Global Trade and Tariffs: Initiatives Underway to Mitigate Challenges
Global Trade and Tariffs: Initiatives Underway to Mitigate Challenges • Initiated a task force that is proactively working to mitigate exposure to tariffs, through a combination of actions including customer surcharges, supply chain, procurement and other initiatives • Based on recent customer discu
Slide 8: Marco Dal Lago
x Marco Dal Lago Chief Financial Officer Q1 2025 Financial Results
Slide 9: Q1 2025: Financial Highlights
Q1 2025: Financial Highlights Q1 2025: Revenue Q1 2025: Margins (€ Million) HVS non-HVS • Gross profit margin increased 80 bps to 27.2% +9% − Strong performance in the BDS Segment driven by: 236 257 ▪ (i) exp. improvements from Latina and Fishers (sites remain margin-dilutive, but gaining operating
Slide 10: Q1 2025: Segment Trends
Q1 2025: Segment Trends Biopharmaceutical and Diagnostic Solutions (BDS) Segment REVENUE Q1 2025 revenue increased 11% (11% at cc), driven by solid growth in HVS: 199 221 (€ Million) • Revenue from HVS grew 25% to €110.3 million, or approx. 50% of BDS revenue in Q1 Q1 2024 Q1 2025 • Continue to see
Slide 11: Balance Sheet and Cash Flow Items
Balance Sheet and Cash Flow Items At Quarter Ended March 31, 2025 € 90.7M € 300.2M Total Cash and Cash Net Debt* Equivalents In Q1 2025 € 69.7M € 99.8M € 29.7M CapEx* Net Cash Generated Free Cash Flow* from Operations __________ *Net Debt, CapEx, Free Cash Flow are non-GAAP financial measures. Pleas
Slide 12: Reflecting Recent Macro Updates into FY 2025 Guidance
Reflecting Recent Macro Updates into FY 2025 Guidance Tariffs Assumptions: • A 10% tariff rate for goods shipping from the E.U. to the U.S., the absorption of price increases from suppliers, and no change in the current U.S. policy • Estimated impact of €4.5M of operating profit and one cent of adj.
Slide 13: Franco Stevanato
x Franco Stevanato Chairman & Chief Executive Officer Q1 2025 Financial Results
Slide 14: Solid start to 2025, and team remains laser-focused on executing against our long-term objectives
Solid start to 2025, and team remains laser-focused on executing against our long-term objectives • Continued strong momentum in the BDS Segment – driven by: (i) progress at our Latina and Fishers sites, (ii) an increase in mix of HVS, and (iii) ongoing stabilization in vial demand • Organization re
Slide 15: Thank You
Stevanato Group Q1 2025 Financial Results Thank You
Slide 16: Reconciliation of Non-GAAP Financial Measures
Reconciliation of Non-GAAP Financial Measures This presentation contains non-GAAP financial measures. Please refer to the tables included in this presentation for a reconciliation of non-GAAP measures. Management monitors and evaluates our operating and financial performance using several non-GAAP f
Slide 17: Reconciliation of Non-GAAP Financial Measures (1/5)
Reconciliation of Non-GAAP Financial Measures (1/5) Reconciliation of Revenue to Constant Currency Revenue Reconciliation of EBITDA (Amounts in € millions) (Amounts in € millions) For the three months Biopharmaceutical Change ended March 31, and 2025 2024 % Diagnostic Net Profit 26.5 18.8 40.9 % Thr
Slide 18: Reconciliation of Non-GAAP Financial Measures (2/5)
Reconciliation of Non-GAAP Financial Measures (2/5) Reconciliation of Reported and Adjusted EBITDA, Operating Profit, Income Taxes, Net Profit, and Diluted EPS (Amounts in € millions, except per share data) Operating Income Three months ended March 31, 2025 EBITDA Net Profit Diluted EPS Profit Taxes
Slide 19: Reconciliation of Non-GAAP Financial Measures (3/5)
Reconciliation of Non-GAAP Financial Measures (3/5) Capital Employed (Amounts in € millions) As of March 31, As of December 2025 31, 2024 - Goodwill and intangible assets 83.1 83.6 - Right of use assets 14.1 15.7 - Property, plant and equipment 1,269.1 1,248.4 - Financial assets - investments FVTPL
Slide 20: Reconciliation of Non-GAAP Financial Measures (4/5)
Reconciliation of Non-GAAP Financial Measures (4/5) CAPEX Net (Debt) / Net Cash (Amounts in € millions) (Amounts in € millions) For the three months As of December Change As of March 31, ended March 31, 31, 2025 2024 € 2025 2024 Addition to Property, plants and equipment 68.3 69.7 (1.4 ) Non-current
Slide 21: Reconciliation of Non-GAAP Financial Measures (5/5)
Reconciliation of Non-GAAP Financial Measures (5/5) Reconciliation of 2025 Guidance* Reported and Adjusted EBITDA, Operating Profit, Net Profit, Diluted EPS (Amounts in € millions, except per share data) Operating Revenue EBITDA Net Profit Diluted EPS Profit 1,160-0- Reported 1,190.0 280.3-293.6 176